ERBB2 and breast carcinoma: demonstrated the efficacy of a HER2-DC vaccine in HER2+ breast cancer patients, where treatment induced a significant increase in anti-HER2 CD4+ TH1 response and improved rates of pathological complete response (160, 163, 219).